What is EpiCypher?
EpiCypher operates at the intersection of biotechnology and advanced molecular research, functioning as a premier research partner dedicated to the complexities of epigenetics. The company provides a comprehensive suite of proprietary tools, including high-precision assays and sophisticated bioinformatics platforms designed to decode chromatin structure and function. By bridging the gap between fundamental biological discovery and clinical application, EpiCypher enables researchers to accelerate drug development and diagnostic innovation. Their market position is defined by a commitment to technical excellence, serving as a vital link in the supply chain for laboratories focused on human health and disease mechanisms.
How much funding has EpiCypher raised?
EpiCypher has raised a total of $992K across 2 funding rounds:
Debt
$350K
Debt
$642K
Debt (2020): $350K with participation from PPP
Debt (2021): $642K led by PPP
Key Investors in EpiCypher
PPP
Public-Private Partnership
What's next for EpiCypher?
With the successful acquisition of this major strategic investment, EpiCypher is well-positioned to expand its footprint in the high-growth epigenetics market. The company is expected to prioritize the scaling of its custom development services and the enhancement of its bioinformatics infrastructure to support increasingly complex clinical trial requirements. As the industry shifts toward personalized medicine, EpiCypher's ability to provide actionable insights into chromatin regulation will likely serve as a key differentiator. Future growth initiatives will likely focus on deepening collaborative ties with global pharmaceutical entities and broadening the reach of their assay portfolio to address emerging therapeutic targets in oncology and rare genetic disorders.
See full EpiCypher company page
